Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HAAO | P46952 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.39 |
| ▸ | GABRP | O00591 | 1/20 | 0.38 |
| ▸ | GABRD | O14764 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.38 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.38 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27577439 | 0.84 | CYP1A2 (0.44) | HAAOCYP1A2ALDH1A1KDM4EHPGD | |
| SCHEMBL3980826 | 0.83 | CYP1A2 (0.42) | HAAOCYP1A2ALDH1A1KDM4EHPGD | |
| SCHEMBL11285953 | 0.83 | NCEH1 (0.44) | HAAOCYP1A2ALDH1A1KDM4EHPGD | |
| SCHEMBL28131931 | 0.81 | KDM4E (0.53) | HAAOCYP1A2ALDH1A1KDM4EHPGD | |
| SCHEMBL27770760 | 0.81 | CYP1A2 (0.41) | HAAOCYP1A2ALDH1A1KDM4EHPGD | |
| SCHEMBL12544237 | 0.81 | SIRT3 (0.41) | ALDH1A1KDM4EHPGDHSD17B10TSHR | |
| SCHEMBL2059304 | 0.81 | CSNK2A1 (0.48) | CYP1A2ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL29370019 | 0.79 | CYP1A2 (0.48) | HAAOCYP1A2ALDH1A1KDM4EHPGD | |
| SCHEMBL242262 | 0.79 | CYP1A2 (0.48) | HAAOCYP1A2ALDH1A1KDM4EHPGD | |
| SCHEMBL28033212 | 0.79 | CYP1A2 (0.48) | HAAOCYP1A2ALDH1A1KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106431969-B | A kind of method for preparing 2- methyl -4- formaldoxime yl benzoic acid methyl esters | 荆门医药工业技术研究院 | 2018-07-06 | — | — | CN | claimed |
| CN-106431969-A | Method for preparing 2-methyl-4-formaldoxime methyl benzoate | 荆门医药工业技术研究院 | 2017-02-22 | — | — | CN | claimed |
| US-10292981-B2 | Oxazoline and isoxazoline derivatives as CRAC modulators | LUPIN LIMITED (IN) | 2019-05-21 | — | — | US | disclosed |
| CN-106431969-B | A kind of method for preparing 2- methyl -4- formaldoxime yl benzoic acid methyl esters | 荆门医药工业技术研究院 | 2018-07-06 | — | — | CN | disclosed |
| WO-2018089433-A1 | PHENYL mTORC INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
| US-20180036317-A1 | METHOD OF TREATING CONDITIONS WITH KINASE INHIBITORS | ALLERGAN INC (US) | 2018-02-08 | — | — | US | disclosed |
| US-9820989-B2 | Method of treating conditions with kinase inhibitors | ALLERGAN, INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-20170304299-A1 | OXAZOLINE AND ISOXAZOLINE DERIVATIVES AS CRAC MODULATORS | LUPIN LTD (IN) | 2017-10-26 | — | — | US | disclosed |
| US-9737534-B2 | Oxazoline and isoxazoline derivatives as CRAC modulators | LUPIN LIMITED (IN) | 2017-08-22 | — | — | US | disclosed |
| US-20170143728-A1 | METHOD OF TREATING CONDITIONS WITH KINASE INHIBITORS | ALLERGAN, INC. | 2017-05-25 | — | — | US | disclosed |
| CN-106431969-A | Method for preparing 2-methyl-4-formaldoxime methyl benzoate | 荆门医药工业技术研究院 | 2017-02-22 | — | — | CN | disclosed |
| EP-1813613-A1 | NOVEL FUSED IMIDAZOLE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-08-01 | — | — | EP | disclosed |
| US-20050124656-A1 | Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases(ptps) | APPLIED RESEARCH SYSTEMS ARS (NL) | 2005-06-09 | — | — | US | disclosed |
| CN-1193000-C | Biphenyl derivatives substituted by an aromatic or heteroaromatic radical and pharmaceutical and cometic compositions containing same | GALDERMA RES & DEV I (FR) | 2005-03-16 | — | — | CN | disclosed |
| EP-1470102-A1 | SUBSTITUTED METHYLENE AMIDE DERIVATIVES AS MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS) | Applied Research Systems ARS Holding N.V. (AN) | 2004-10-27 | — | — | EP | disclosed |
| US-6800444-B1 | USEFUL AS ANTIBACTERIAL AND OTHER PHARMACEUTICAL AGENTS/INTERMEDIATES | ISIS PHARMACEUTICALS, INC. | 2004-10-05 | — | — | US | disclosed |
| WO-2003064376-A1 | SUBSTITUTED METHYLENE AMIDE DERIVATIVES AS MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS) | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2003-08-07 | — | — | WO | disclosed |
| CN-1236354-A | Aryl-or heteroaryl-substituted biphenyl derivatives and pharmaceutical and cosmetic compositions containing them | GALDERMA RES & DEV (FR) | 1999-11-24 | — | — | CN | disclosed |
| US-5780241-A | ALTERING ELECTROCHEMICAL PROPERTIES BY DECYCLIZATION | ISIS PHARMACEUTICALS, INC. (US) | 1998-07-14 | — | — | US | disclosed |
| WO-1998020349-A1 | COMPLEX CHEMICAL LIBRARIES | ISIS PHARMACEUTICALS, INC. (US) | 1998-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180036317-A1 | METHOD OF TREATING CONDITIONS WITH KINASE INHIBITORS | MAP3K1, MAPK1, MAP3K2 | HAAO 2032/4885CYP1A2 2753/4885ALDH1A1 1159/4885 |
| US-10292981-B2 | Oxazoline and isoxazoline derivatives as CRAC modulators | RYR2, RYR1, ADRA2C | HAAO 1947/4885CYP1A2 213/4885ALDH1A1 655/4885 |
| US-20170304299-A1 | OXAZOLINE AND ISOXAZOLINE DERIVATIVES AS CRAC MODULATORS | RYR2, ADRA2C, RYR1 | HAAO 1919/4885CYP1A2 183/4885ALDH1A1 607/4885 |
| US-20050124656-A1 | Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases(ptps) | PTPRS, PTPA, PTPMT1 | HAAO 1485/4885CYP1A2 3016/4885ALDH1A1 3733/4885 |
| US-20170143728-A1 | METHOD OF TREATING CONDITIONS WITH KINASE INHIBITORS | MAP3K1, MAPK1, MAP3K2 | HAAO 2032/4885CYP1A2 2753/4885ALDH1A1 1159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.